Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Novartis AGNYSE: NVS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA declines year over year

Q2 FY2026 EBITDA of $5.94B fell 2.3% year over year, in line with the -2.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 9.7% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.

Context

  • EBITDA amounted to 41.9% of revenue in FY2025, up 1.9 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 12 analysts of $24.51B (+6.6%) for the fiscal year ending Dec 2026, a slowdown from the +11.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.94B+9.7% QoQ
Last fiscal yearDec 2025
$22.99B+11.0% YoY
LTMJun 2026
$22.26B-2.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.3%+48.5%+50.8 pp
1 year+11.0%+6.6%-4.3 pp
3-year CAGR+16.1%+6.8%-9.3 pp
5-year CAGR+7.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
22.99B USD
Year-over-year change
+11.0%
4-year CAGR
-7.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.0% is the 7th highest of 11, against a peer median of +3.4%.
  • EBITDA amounts to 40.0% of revenue for NVS, versus a peer median of 30.6%.
NVS Competitors
EBITDA for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 180.91B DKK+4.7%+26.8%54.9%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$16.82B USD+11.6%-7.5%34.2%
SNYSanofiLTM Jun 2026€14.77B EUR+15.5%-2.6%30.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
GILDGilead Sciences, Inc.LTM Jun 2026$1.33B USD-87.8%+15.3%4.4%
Peer median (excluding NVS) —+3.4%+8.2%30.6%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.97B43.46B46.66B51.72B54.81B
Cost of Revenue11.74B11.58B12.47B12.83B13.69B
Gross Profit32.24B31.88B34.19B38.9B41.12B
Gross Margin73.3%73.4%73.3%75.2%75.0%
Research & Development8.64B9.17B11.37B10.02B10.74B
Selling, General & Admin12.83B12.19B12.52B12.57B13.31B
Operating Expenses22.18B23.93B24.42B24.35B24.05B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
EBITDA30.91B14.68B18.26B20.72B22.99B
EBITDA Margin70.3%33.8%39.1%40.1%41.9%
Operating Income10.06B7.95B9.77B14.54B17.07B
Operating Margin22.9%18.3%20.9%28.1%31.2%
Interest Income71M377.74M629.24M567.68M374.91M
Interest Expense905M834.62M876.12M1.04B1.19B
Other Income / Expenses14.47B(769M)(646M)(904M)(638.25M)
Income Before Tax24.53B7.18B9.12B13.64B16.44B
Pre-Tax Margin55.8%16.5%19.6%26.4%30.0%
Income Tax Expense1.63B1.13B551M1.7B2.4B
Net Income24.02B6.96B14.85B11.94B14.06B
Net Margin54.6%16.0%31.8%23.1%25.6%
EPS (Basic)10.713.197.155.927.25
EPS (Diluted)10.633.177.105.877.19
Weighted Avg Shares2.24B2.18B2.08B2.02B1.94B
Weighted Avg Shares (Diluted)2.26B2.2B2.09B2.04B1.96B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.